erdafitinib: Clinical Trials

22 trials of erdafitinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 active not recruiting, 5 completed, 4 terminated, 1 not yet recruiting. 22 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 222Active not recruiting 10, Completed 5, Terminated 4, Not yet recruiting 1, Recruiting 1, Withdrawn 1
Phase 14Active not recruiting 2, Completed 2

Follow erdafitinib: new trials by email Literature Review of erdafitinib trials Research Report on erdafitinib

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour
Phase 2Not yet recruitingPeking University Shenzhen Hospital2002025-01-012024-11-18
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging - Recurrent Glioma, Recurrent WHO Grade 2 Glioma
Phase 2Active not recruitingNational Cancer Institute (NCI)302024-01-042026-10-15
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma
Phase 2WithdrawnNational Cancer Institute (NCI)2023-10-122025-10-21
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Erdafitinib Intravesical Delivery System - Non-Muscle Invasive Bladder Neoplasms
Phase 1 / Phase 2Active not recruitingJanssen Research & Development, LLC2352022-04-112026-11-03
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Erdafitinib - Bladder Cancer, Recurrent Bladder Cancer
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center202022-02-172026-09-02
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
Biopsy, Biospecimen Collection, Erdafitinib - Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
Phase 2TerminatedM.D. Anderson Cancer Center112021-07-152026-02-06
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Abiraterone Acetate, Enzalutamide, Erdafitinib - Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma
Phase 2TerminatedUniversity of Washington32020-04-272023-09-28
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C) - Urinary Bladder Neoplasms
Phase 2CompletedJanssen Research & Development, LLC1072020-02-282026-02-24
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Erdafitinib - Advanced Solid Tumor
Phase 2CompletedJanssen Research & Development, LLC3162019-11-202026-09-17
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma
Phase 1 / Phase 2CompletedMultiple Myeloma Research Consortium1032019-04-012025-02-14
FGFR Inhibitor in FGFR Dysregulated Cancer
ERDAFITINIB - Lung Cancer, NSCLC
Phase 2TerminatedLung Cancer Group Cologne222019-03-252023-06-09
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)352018-08-202026-09-15
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)352018-07-032026-10-15
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)202018-06-052026-11-13
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Erdafitinib, Cetrelimab, Cisplatin - Urothelial Carcinoma
Phase 1 / Phase 2Active not recruitingJanssen Research & Development, LLC1252018-04-052026-08-28
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-11-13
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
JNJ-42756493, Dexamethasone - Multiple Myeloma, Relapsed/Refractory
Phase 2TerminatedUniversity Health Network, Toronto202017-06-132020-09-17
The Drug Rediscovery Protocol (DRUP Trial)
Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors
Phase 2RecruitingThe Netherlands Cancer Institute15502016-08-012024-01-24
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Erdafitinib - Neoplasm
Phase 2CompletedJanssen Research & Development, LLC352016-07-082025-04-27
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)64522015-08-172026-11-12

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Glioma (4)  ·  Multiple Myeloma (4)  ·  Urinary Bladder Neoplasms (4)  ·  Non-Muscle Invasive Bladder Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Transitional Cell (2)  ·  Central Nervous System Neoplasms (2)  ·  Ependymoma (2)  ·  Esophageal Neoplasms (2)  ·  Hepatoblastoma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Lung Neoplasms (2)  ·  Lymphoma (2)

Sponsors

Janssen Research & Development, LLC (7)  ·  National Cancer Institute (NCI) (7)  ·  Lung Cancer Group Cologne (1)  ·  M.D. Anderson Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Multiple Myeloma Research Consortium (1)  ·  Peking University Shenzhen Hospital (1)  ·  The Netherlands Cancer Institute (1)  ·  University Health Network, Toronto (1)  ·  University of Washington (1)

Countries

United States (15)  ·  South Korea (7)  ·  Taiwan (6)  ·  Germany (5)  ·  Spain (5)  ·  Belgium (4)  ·  China (4)  ·  France (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Brazil (3)  ·  Canada (3)  ·  Italy (3)  ·  Japan (3)  ·  Poland (3)

Top investigators

Alain C Mita (2)  ·  Alice Lee (1)  ·  Di Maria Jiang (1)  ·  Donald W Parsons (1)  ·  E.E. Voest, prof. (1)  ·  Eugene Pietzak, MD (1)  ·  Hearn J Cho, M.D., Ph.D. (1)  ·  Keith T Flaherty (1)  ·  Lucia Nogova, MD (1)  ·  Michael Schweizer (1)  ·  Paul Corn (1)  ·  Suzanne Trudel, M.D. (1)

Results publications

PMID 26586415, PMID 31340094, PMID 31401903, PMID 32463741, PMID 33048619, PMID 33591402, PMID 34125951, PMID 34977972, PMID 35030333, PMID 35086719, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35598186, PMID 36351402, PMID 36639200, PMID 36870947, PMID 37053535, PMID 37322121, PMID 37424386, PMID 37541273, PMID 37934000, PMID 38591867, PMID 38630551, PMID 39138436, PMID 39666929, PMID 39693587, PMID 39913886, PMID 39971605, PMID 40675687, PMID 40865033, PMID 41066729, PMID 41166674, PMID 41538748, PMID 41986720, PMID 42456086, PMID 42686334

NIH funding

2023 (5), U10CA180820 (3), 2019 (2), U10CA180886 (2), UM1CA186644 (2), 2014 (1), 2017 (1), 2018 (1), U24CA196172 (1), UM1CA081457 (1)